The company associated with Dovato is ViiV Healthcare [1]. ViiV Healthcare is a global specialist HIV company established in 2009 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi later joining as a third partner [1].
What is Dovato used for?
Dovato is a complete, single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who have no known history of antiretroviral treatment-induced resistance to any of the drugs in Dovato [2]. It is also indicated for HIV-1 infected adults and adolescents (12 years of age and older and weighing at least 35 kg) to replace the current antiretroviral regimen in those who have achieved and maintained viral suppression (HIV-1 RNA < 50 copies/mL) on their current regimen for at least 6 months, and who have no history of drug resistance or prior virologic failure [2].
What are the active ingredients in Dovato?
Dovato contains two active ingredients: dolutegravir and lamivudine [3]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) [3].
How effective is Dovato?
Clinical trials have demonstrated that Dovato is effective in achieving and maintaining viral suppression in eligible adult patients [2]. For instance, in the ADVANCE study, HIV-1 infected adults with no prior antiretroviral treatment resistance received Dovato and achieved high rates of virologic suppression, with no treatment-emergent resistance observed [2].
What are the potential side effects of Dovato?
Common side effects reported with Dovato include headache, diarrhea, nausea, and fatigue [2]. Serious side effects can include hypersensitivity reactions, and liver problems in patients who are coinfected with Hepatitis B virus [2]. Patients with pre-existing liver enzyme abnormalities may be at increased risk [2].
When does Dovato's patent expire?
Information regarding the specific patent expiry dates for Dovato is available through resources like DrugPatentWatch.com. These resources track the patent landscape for pharmaceuticals, including the expected expiration of patents that grant market exclusivity [4]. Generally, patent protection for drugs provides a period of market exclusivity before generic or biosimilar versions can be introduced [4].
Who are Dovato's competitors?
Dovato competes with other single-tablet regimens and combination therapies used for HIV treatment. These include other INSTI-based regimens as well as treatments from different drug classes [5]. The competitive landscape for HIV medications is dynamic, with ongoing development of new formulations and treatments [5].